Globus Medical Inc. Class A Common Stock vs SkyWest Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while SkyWest Inc trades at $90.69 (market cap $3.59B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.9× SkyWest Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and SkyWest Inc for 8 Days on average.
| GMED | SKYW | |
|---|---|---|
Market Cap | $10.25B | $3.59B |
Volume | 1,059,528 | 419,815 |
Sector | Health | Industrials |
52-Week High | $96.82 | $115.94 |
52-Week Low | $58.33 | $78.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $9.76B | $5.37B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SkyWest (SKYW) trades at $94.52, down 0.53% with a bearish technical signal despite positive analyst sentiment. The stock shows mixed earnings performance with a recent Q1 2026 beat but Q2 2026 miss, while maintaining solid fundamentals including a 9.78% net income margin and attractive valuation at 9.39 P/E. Recent news highlights fleet modernization efforts and expanding flying agreements as growth catalysts amid cost pressures.
The stock presents a compelling value opportunity with 58.8% analyst buy ratings and $112 consensus target, offering 18.5% upside potential. However, technical weakness and executive stock sales create near-term headwinds. Long-term prospects remain positive driven by operational improvements and strategic partnerships, though investors should monitor cost management and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →